KR20250131845A - 고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도 - Google Patents

고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도

Info

Publication number
KR20250131845A
KR20250131845A KR1020257024220A KR20257024220A KR20250131845A KR 20250131845 A KR20250131845 A KR 20250131845A KR 1020257024220 A KR1020257024220 A KR 1020257024220A KR 20257024220 A KR20257024220 A KR 20257024220A KR 20250131845 A KR20250131845 A KR 20250131845A
Authority
KR
South Korea
Prior art keywords
compound
independently
alkyl
chemical formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257024220A
Other languages
English (en)
Korean (ko)
Inventor
램지 베버릿지
제이슨 버치
스테판 시블라
패트릭 시르
Original Assignee
벤투스 테라퓨틱스 유에스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤투스 테라퓨틱스 유에스 인코포레이티드 filed Critical 벤투스 테라퓨틱스 유에스 인코포레이티드
Publication of KR20250131845A publication Critical patent/KR20250131845A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257024220A 2022-12-20 2023-12-19 고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도 Pending KR20250131845A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263433987P 2022-12-20 2022-12-20
US63/433,987 2022-12-20
US202363501320P 2023-05-10 2023-05-10
US63/501,320 2023-05-10
PCT/US2023/084787 WO2024137607A1 (en) 2022-12-20 2023-12-19 Thiadiazole derivatives as inhibitors of cyclic gmp-amp synthase and uses thereof

Publications (1)

Publication Number Publication Date
KR20250131845A true KR20250131845A (ko) 2025-09-03

Family

ID=89768384

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257024220A Pending KR20250131845A (ko) 2022-12-20 2023-12-19 고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도

Country Status (12)

Country Link
US (1) US20240270740A1 (https=)
EP (1) EP4638446A1 (https=)
JP (1) JP2026501225A (https=)
KR (1) KR20250131845A (https=)
CN (1) CN120530109A (https=)
AU (1) AU2023408761A1 (https=)
CL (1) CL2025001819A1 (https=)
CO (1) CO2025007987A2 (https=)
IL (1) IL321525A (https=)
MX (1) MX2025007158A (https=)
TW (1) TW202434205A (https=)
WO (1) WO2024137607A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026077404A1 (zh) * 2024-10-10 2026-04-16 北京知维拓医药科技有限公司 一种杂环类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2017176812A1 (en) * 2016-04-05 2017-10-12 Immune Sensor, Llc cGAS ANTAGONIST COMPOUNDS
SG11202002218VA (en) * 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
BR112020016008A2 (pt) 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica
WO2020072492A1 (en) * 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists
JP7781074B2 (ja) * 2020-05-20 2025-12-05 エフ． ホフマン－ラ ロシュ アーゲー Ｃｇａｓ阻害トリアゾロピリミドン誘導体
EP4267571A1 (en) * 2020-12-22 2023-11-01 Novartis AG Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
CA3236877A1 (en) * 2021-11-08 2023-05-11 Ventus Therapeutics U.S., Inc. Heterocyclic compounds and uses thereof
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Also Published As

Publication number Publication date
CN120530109A (zh) 2025-08-22
TW202434205A (zh) 2024-09-01
AU2023408761A1 (en) 2025-06-19
MX2025007158A (es) 2025-07-01
CL2025001819A1 (es) 2025-09-26
WO2024137607A1 (en) 2024-06-27
US20240270740A1 (en) 2024-08-15
JP2026501225A (ja) 2026-01-14
EP4638446A1 (en) 2025-10-29
IL321525A (en) 2025-08-01
CO2025007987A2 (es) 2025-09-08

Similar Documents

Publication Publication Date Title
US11891365B2 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
KR102638678B1 (ko) 헤테로시클릭 화합물
KR20250131845A (ko) 고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도
WO2024233767A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
EP4652164A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
CN116332905B (zh) (s)-n-苯基-1-(吡啶-2-基)吡咯烷-2-甲酰胺衍生物
CN116348472B (zh) 大环化合物
WO2025155786A1 (en) Bicyclic tyrosine kinase 2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)